Pep Mogul retweeted
On this day 88 years ago, a Swiss chemist made LSD for the first time.
He wanted a drug for blood circulation, but it failed. 5 years later he made it again, got a trace on his fingertips, and had the first acid trip in history.
He lived to 102.
The potency gap between retatrutide and other GLP-1s is hard to overstate.
Ozempic is the drug that took this whole category mainstream. Reta helped people lose more than twice as much weight in a head-to-head trial!
Is it going to become the best-selling drug of all time?
24 weight-loss drugs, ranked by how much weight people lost compared with placebo.
Retatrutide is #1 at 22%.
Pep Mogul retweeted
I suspect the best use for a GLP-1 pill will be keeping the weight off.
People who lost over 21% on tirzepatide, then switched to a daily pill, kept 75% of that loss a year later. On placebo, 49%.
The pill is Eli Lilly's orforglipron, and it was just approved in China!
BREAKING: Hims & Hers CEO Andrew Dudum just called Superpower's Peptide Library "so smooth."
15
2,136
Read more:
newsroom.heart.org/news/glp-…
So you're telling me Ozempic could've existed 27 years earlier? And Pfizer killed it because they thought injections would never sell?
In some very real sense, Ozempic was invented in 1990. Pfizer is the reason it took until 2017.
A small biotech and Pfizer infused GLP-1 into diabetics for several days that year. It lowered blood glucose, slowed gastric emptying and reduced hunger.
Basically, the same 3 things that make Ozempic work today.
Pfizer had signed a $30M deal for exclusive rights to the program 2 years earlier. Then senior leadership decided there would never be another injectable diabetes drug besides insulin, and pulled out.
Why? Nobody ever said.
And they never published any of it. The joint venture agreement said internal data stayed internal, and that was that.
The patents went back to the hospital in Boston. Novo picked them up in 1992, and Ozempic was approved in 2017.
Ozempic could've existed 27 years ago.
I suspect there are more Ozempics sitting in filing cabinets right now, killed by someone's hunch about what patients would never want.
5
468
Read more:
newsroom.heart.org/news/glp-…
This man took Semax for a week to treat his anhedonia, anxiety and dysthymia.
He’s 16 months clean from hard drugs and 6 months clean and sober.
His log:
Day 0: “I score 12 points on the depression self assessment and 11 points on the anxiety self assessment.”
Day 2: “I think I felt joy for the first time in recovery while I was alone.”
Day 5: “I listen to music and am able to appreciate it creatively and emotionally instead of just mechanically. I feel like I’m returning to my old self.”
Day 6: “I got a 2 depression score and a 2 anxiety score.”
Could be placebo though.
Nevertheless, I hope the effect was permanent.
Semax is one of the best nootropics on the market right now, and US pharmacies can now compound it.
In my own experiments, it’s what I reach for on heavy cognitive days, mostly during deep work.
And the science behind it goes deeper than most people think: (1/14)
1
6
562
Pep Mogul retweeted
Semax is one of the best nootropics on the market right now, and US pharmacies can now compound it.
In my own experiments, it’s what I reach for on heavy cognitive days, mostly during deep work.
And the science behind it goes deeper than most people think: (1/14)
“The future is already here, it’s just not very evenly distributed.” (William Gibson)
Peptides are the clearest example of that I can think of right now.
The peptide field has been compounding for a century, and the last 12 months were its biggest yet:
- The first drugmaker to hit a $1 trillion valuation got there on a peptide
- Retatrutide read out 5 Phase 3 trials, and in the main obesity one, 45.3% of people on the top dose lost 30%+ of their weight (bariatric surgery territory)
- The first oral peptide for psoriasis got approved, and 65% had clear or almost clear skin at 16 weeks vs. 8% on placebo
- A daily peptide pill that lowers LDL cholesterol by more than half got approved
- Retatrutide delivered more than double the weight loss of Ozempic in a head-to-head Phase 3 (20.9% vs. 9.4%)
- The first GLP-1 pill for weight loss got FDA approved
- BPC-157 is finally getting a proper human trial for injury recovery (randomized, double-blind, placebo-controlled)
- HHS released a policy which makes 6 peptides accessible through compounding pharmacies, including BPC-157, MOTS-c and Epitalon
For most people, peptides still sit in biohacker territory.
I think 5 to 10 years from now, the majority of people will be taking some sort of enhancement therapeutic.
2
425




















